Headlines about Gilead Sciences (NASDAQ:GILD) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Gilead Sciences earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.9584728578395 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news stories that may have effected Accern’s analysis:

Shares of Gilead Sciences (NASDAQ GILD) traded down $1.20 during midday trading on Tuesday, reaching $87.60. The company’s stock had a trading volume of 4,486,695 shares, compared to its average volume of 8,703,882. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $89.54. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The company has a market cap of $114,160.00, a P/E ratio of 9.94, a P/E/G ratio of -1.89 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter last year, the company earned $2.75 EPS. The firm’s revenue was down 13.2% compared to the same quarter last year. equities research analysts predict that Gilead Sciences will post 8.53 EPS for the current fiscal year.

A number of brokerages recently issued reports on GILD. Citigroup upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and cut their target price for the stock from $88.80 to $76.00 in a report on Tuesday. Leerink Swann increased their price target on Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a research report on Thursday, October 19th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, October 19th. Mizuho increased their price target on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Finally, Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target for the company. in a research report on Wednesday, January 17th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $85.58.

In other news, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the sale, the insider now owns 3,046,766 shares of the company’s stock, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 591,666 shares of company stock valued at $44,466,567. 1.30% of the stock is owned by corporate insiders.

WARNING: “Gilead Sciences (GILD) Getting Somewhat Favorable Press Coverage, Report Shows” was published by Marea Informative and is owned by of Marea Informative. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.mareainformativa.com/2018/01/30/gilead-sciences-gild-getting-somewhat-positive-press-coverage-study-shows-updated-updated-updated.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.